---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316067"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-07-24T20:05:14+00:00"
generated_at: "2026-07-24T20:06:12.514900+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives Nasdaq delisting notice for bid price non-compliance

## Summary
- Nasdaq Staff Determination on July 22, 2026: bid price below $1.00 for 30 consecutive business days (June 8–July 21, 2026).
- Company ineligible for 180-day cure period due to reverse stock split within prior year (Listing Rule 5810(c)(3)(A)(iv)).
- Delisting scheduled for July 31, 2026 unless appeal requested by July 29, 2026; company intends to request hearing.
- At hearing, company will present plan to regain compliance; no assurance of success.

## SEC filing metadata
- accession: 0001193125-26-316067
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-07-24T20:05:14+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/0001193125-26-316067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/fblg-20260722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316067
- JSON: https://secwatch.observer/filing/0001193125-26-316067.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.